Insulin efsitora alfa

DB19013ApprovedProtein Based Therapies

Insulin efsitora alfa is a long-acting insulin analog fused to a human IgG2 Fc region, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Mechanism
Curator reviewed · 4 references
Primary indication
Insulin efsitora alfa is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Curator reviewed · 1 structured indication
First approval
United States, 2026
Also known as
Insulin efsitora
Code names
LY-3209590

Resolves to

Clinical / RWD
Targets
Transporters

What you can answer from here — as of October 28, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
863Drug interactionsStructured to mechanism, not free text
Sign in
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
2Marketed productsAcross 1 country and 1 labeller
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Insulin efsitora alfa, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account